Minerva Endocrinologica 2012 June;37(2)

ENDOCRINE ONCOLOGY  

Minerva Endocrinologica 2012 June;37(2):103-15

Thyroid cancer development and progression: emerging role of cancer stem cells

Malaguarnera R., Morcavallo A., Giuliano S., Belfiore A.

Abstract PDF

ENDOCRINE ONCOLOGY  

Minerva Endocrinologica 2012 June;37(2):117-32

Endometrial carcinoma tumorigenesis and pharmacotherapy research

Shu J., Fang S., Teichman P. G., Xing L., Huang H.

Abstract PDF

ENDOCRINE ONCOLOGY  

Minerva Endocrinologica 2012 June;37(2):133-9

Molecular genetics of adrenocortical tumor formation and potential pharmacologic targets

Rauschecker M., Stratakis C. A.

Abstract PDF

ENDOCRINE ONCOLOGY  

Minerva Endocrinologica 2012 June;37(2):141-56

Pheochromocytoma: implications in tumorigenesis and the actual management

Shah U., Giubellino A., Pacak K.

Abstract PDF

ENDOCRINE ONCOLOGY  

Minerva Endocrinologica 2012 June;37(2):157-72

The molecular pathogenesis of pituitary tumors: implications for clinical management

Dworakowska D., Grossman A. B.

Abstract PDF

ENDOCRINE ONCOLOGY  

Minerva Endocrinologica 2012 June;37(2):173-85

Role of the IGF axis in prostate cancer

Biernacka K. M., Perks C. M., Holly J. M. P.

Abstract PDF

ORIGINAL ARTICLES  

Minerva Endocrinologica 2012 June;37(2):187-93

Is NAFLD an independent risk factor for increased IMT in T2DM?

Cakır E., Ozbek M., Colak N., Cakal E., Delıbaşi T.

Abstract PDF

ORIGINAL ARTICLES  

Minerva Endocrinologica 2012 June;37(2):195-200

Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial

Zangiabadi N., Shafiee K., Alavi K. H., Assadi A. R., Damavandi M.

Abstract PDF

CASE REPORTS  

Minerva Endocrinologica 2012 June;37(2):201-9

A case of GH deficiency and beta-thalassemia

Smacchia M. P., Mercuri V., Antonetti L., Bassotti G., D’Amico T., Pietrobono D., Gargiulo P.

Abstract PDF